Friday, June 19, 2026

biotech · Generalized Myasthenia Gravis · Leukemia, Myeloid, Acute · VOR

Vor Biopharma

Vor Biopharma clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cambridge, USA HQ
110 Employees
Public company Type
VOR · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Employees
110
Programs
6
Drugs
4
Patents
12
Intelligence · Clinical Programs

Vor Biopharma projects

4 ClinicalTrials.gov programs sponsored by Vor Biopharma.

Vor Biopharma has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. RC18G006

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial
  2. Telitacicept

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial
  3. Telitacicept

    Vor Biopharma

    Primary Sjogren's Disease

    phase 3 mab active

    1 trial
  4. Telitacicept

    Vor Biopharma

    Systemic Lupus Erythematosus

    phase 3 mab terminated

    2 trials

Frequently asked questions

How many clinical projects does Vor Biopharma have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.